Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
PerkinElmer Inc is a diagnostics & research business based in the US. PerkinElmer shares (PKI) are listed on the NYSE and all prices are listed in US Dollars. PerkinElmer employs 16,000 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $145.53 |
|---|---|
| 52-week range | $132.78 - $202.99 |
| 50-day moving average | $147.79 |
| 200-day moving average | $171.36 |
| Wall St. target price | $178.64 |
| PE ratio | 23.4193 |
| Dividend yield | $0.28 (0.21%) |
| Earnings per share (TTM) | $6.16 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $145.53 from 2022-06-24
| 1 week (2022-06-17) | 7.87% |
|---|---|
| 1 month (2022-05-22) | N/A |
| 3 months (2022-03-24) | -18.85% |
| 6 months (2021-12-23) | -24.90% |
| 1 year (2021-06-25) | -4.53% |
|---|---|
| 2 years (2020-06-26) | 54.93% |
| 3 years (2019-06-26) | 54.97% |
| 5 years (2017-06-26) | 113.70% |
Valuing PerkinElmer stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PerkinElmer's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
PerkinElmer's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 23x. In other words, PerkinElmer shares trade at around 23x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
PerkinElmer's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.2269. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into PerkinElmer's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
PerkinElmer's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.7 billion.
The EBITDA is a measure of a PerkinElmer's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $5 billion |
|---|---|
| Operating margin TTM | 26.42% |
| Gross profit TTM | $2.9 billion |
| Return on assets TTM | 7.02% |
| Return on equity TTM | 13.25% |
| Profit margin | 14.76% |
| Book value | $56.97 |
| Market capitalisation | $18.2 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like PerkinElmer.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 21.66
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and PerkinElmer's overall score of 21.66 (as at 12/31/2018) is pretty good – landing it in it in the 25th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like PerkinElmer is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.15/100
PerkinElmer's environmental score of 3.15 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that PerkinElmer is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 12.09/100
PerkinElmer's social score of 12.09 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that PerkinElmer is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 9.42/100
PerkinElmer's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that PerkinElmer is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. PerkinElmer scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that PerkinElmer has, for the most part, managed to keep its nose clean.
PerkinElmer Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 21.66 |
|---|---|
| Total ESG percentile | 24.92 |
| Environmental score | 3.15 |
| Environmental score percentile | 4 |
| Social score | 12.09 |
| Social score percentile | 4 |
| Governance score | 9.42 |
| Governance score percentile | 4 |
| Level of controversy | 2 |
Dividend payout ratio: 2.77% of net profits
Recently PerkinElmer has paid out, on average, around 2.77% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.21% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), PerkinElmer shareholders could enjoy a 0.21% return on their shares, in the form of dividend payments. In PerkinElmer's case, that would currently equate to about $0.28 per share.
While PerkinElmer's payout ratio might seem low, this can signify that PerkinElmer is investing more in its future growth.
PerkinElmer's most recent dividend payout was on 11 August 2022. The latest dividend was paid out to all shareholders who bought their shares by 20 July 2022 (the "ex-dividend date").
PerkinElmer's shares were split on a 2:1 basis on 3 June 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your PerkinElmer shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for PerkinElmer shares which in turn could have impacted PerkinElmer's share price.
Over the last 12 months, PerkinElmer's shares have ranged in value from as little as $132.78 up to $202.993. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while PerkinElmer's is 1.1538. This would suggest that PerkinElmer's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Everything we know about the NYIAX IPO, plus information on how to buy in.
Everything we know about the Adamas One Corp IPO, plus information on how to buy in.
Everything we know about the Glucose Health IPO, plus information on how to buy in.
Everything we know about the Boustead Wavefront IPO, plus information on how to buy in.
Everything we know about the ParaZero Technologies IPO, plus information on how to buy in.